Actively Recruiting
Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy
Led by Hôpital Européen Marseille · Updated on 2025-09-25
80
Participants Needed
1
Research Sites
356 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Spondyloarthritis (SpA) is a group of inflammatory rheumatic disorders that mainly manifested by inflammatory pain of the spine, pelvis and sometimes limbs. Classically, SpA has been classified into several subtypes, such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated. Several studies have shown specific changes in the gut microbiota during SpA. A recent, uncontrolled study suggested that the therapeutic response to anti-TNFα (Tumor Necrosis Factor) therapy could be predicted by analysis of the gut microbiota. The purpose of the study MEDIBIOTE 3 is to confirm that in SpA, the composition of the intestinal microbiota at the initiation of treatment is predictive of the response to treatment with biotherapy (anti-TNFα / anti-IL17).
CONDITIONS
Official Title
Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with spondyloarthritis or axial type psoriatic arthritis according to ASAS criteria
- Require treatment with anti-TNF alpha or anti-IL-17 as recommended by the French Society of Rheumatology
- Have not received biotherapy previously
- Aged 18 years or older
- Provided free and informed written consent
- Affiliated with the national social security system
- Healthy volunteers without spondyloarthritis or other chronic diseases
- Aged 18 years or older
- Provided free and informed written consent
- Affiliated with or benefiting from a social security scheme
You will not qualify if you...
- Treated with antibiotics, probiotics, prebiotics, or any treatment affecting gut microbiota within one month before stool sampling
- Have another chronic disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Européen Marseille
Marseille, France
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here